Advanced Solutions
for Advanced Pathology
PAX-2 (Polyclonal)
Rabbit Polyclonal Antibody
Cat. No. Description
Volume
44365 PAX-2 RTU R (Poly)
7 ml Ready To Use
44750 PAX-2 0,1 R (Poly)
100 µl liquid Concentrated
44751 PAX-2 1 R (Poly)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Renal Cell Carcinoma
Stability
Up to 36 mo. at 2-8°C
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
Product Description
PAX-2 is a homeogene strongly expressed during kidney development. PAX-2 gene is expressed in the metanephric mesenchyma after ureter
bud induction and is a key factor for the mesenchyma-epithelium conversion. Animals transgenic for PAX-2 have severe renal abnormalities and
cysts but no solid tumoral features. The oncogenic potential of the PAX gene family has been reported in vitro with transformation of cell cultures
and in vivo with cell injections in nude mice. Gnarra et al. showed PAX-2 expression in renal carcinoma cell lines and underlined its potential role
in cell proliferation in these lines. Mazal et al. demonstrated anti-PAX-2 nuclear expression in 88% of clear cell renal cell carcinomas as well as
18% of papillary renal cell carcinoma, and 13% of chromophobe renal cell carcinomas. More recently, O’Connor et al. demonstrated utility in
distinguishing ovarian serous papillary carcinoma (anti-PAX-2 positive) from primary breast carcinoma (anti-PAX-2 negative). Anti-PAX-2 has also
been used to distinguish hepatocellular carcinoma (anti-PAX-2 negative) from clear cell renal cell carcinoma.
Prostate Lesions
PAX-2
PSA/PSAP P504s
CK, 34βE12
p63
CK 7
Thrombo-
modulin Uroplakin III
Prostate Carcinoma
-
+
+
-
-
-
-
-
Urothelial Carcinoma
-
-
-
+
+
+
+
+
Nephrogenic Adenoma
+
-
+
+/-
-
+
-
-
Kidney: Renal Epithelial Tumors
PAX-2
RCC
CD10
Vimentin Ksp-cadherin Parvalbumin CD117
Ep-CAM
Clear Cell RCC
+
+
+
+
-
-
-
-
Chromophobe RCC
+
-/+
-/+
-
+
+
+
+
Oncocytoma
+
-
+/-
-
+/-
+
+
-
Reference
1. Daniel L, et al. Hum Pathol. 2001 Mar; 32(3):282-7.
2. Gnarra JR, Dressler GR. Cancer Res. 1995 Sep 15; 55(18):4092-8.
3. Mazal PR, et al. Mod Pathol. 2005 Apr; 18(4):535-40.
195
